EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lacosamide Safety During Pregnancy and Breastfeeding: A Single-Centre Experience and Comprehensive Narrative Review

Kamila Saramak iD, Manuela Kaml, Marina Peball iD, Luisa Delazer iD, Gerald Walser, Anna Hussl, Iris Unterberger, Alexandra Astner-Rohracher

Pharmacy · 01.04.2026 · 14 (2) · 58

DOI: 10.3390/pharmacy14020058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacy, online erschienen am 01.04.2026. Verfasst von Kamila Saramak und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

The management of epilepsy during pregnancy requires balancing effective seizure control against potential teratogenic effects of antiseizure medications (ASMs). Data on the safety of lacosamide (LCM), a third-generation ASM, during pregnancy and breastfeeding are limited. (2)

Methods

To evaluate the safety and efficacy of LCM during pregnancy and breastfeeding, we report a single-centre case series and provide a comprehensive narrative review of the literature. (3)

Results

In total, 22 cases of maternal exposure to LCM throughout pregnancy (1 monotherapy, 21 polytherapy) were identified, resulting in 21 live births (95.5%). Congenital malformations (atrial septal defect) were observed in one offspring exposed to LCM and levetiracetam (4.8%). Twelve newborns were breastfed (57.1%) without neurodevelopmental delay after twelve months. The literature search identified 16 studies, overall reporting data on 627 pregnancies with LCM (236 monotherapy, 391 polytherapy). Among 632 available pregnancy outcomes (3 twin pregnancies and 1 triplet in the polytherapy group) the proportion of live births was 81.3% (514/632). Major congenital malformations were reported in 2.5% (6/236) with LCM monotherapy and 11.9% (47/396) with polytherapy. (4)

Conclusions

According to the literature, no major safety concerns, especially in LCM monotherapy, and no specific malformations associated with LCM exposure were identified. Conclusions are limited by the heterogeneity of studies and the small number of monotherapy-exposed cases. Larger, prospective studies with longer follow-up are required.

Schlagwörter

Stichwörter der Autor:innen

antiseizure medicationsbreastfeedingepilepsylacosamidepregnancy

Autor:innen und Institutionen

  • Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria.

ORCID-Profile: Kamila Saramak, Marina Peball, Luisa Delazer

Zitieren

APA

Saramak, K., Kaml, M., Peball, M., Delazer, L., Walser, G., Hussl, A., Unterberger, I., & Astner-Rohracher, A. (2026). Lacosamide Safety During Pregnancy and Breastfeeding: A Single-Centre Experience and Comprehensive Narrative Review. Pharmacy, 14(2), 58. https://doi.org/10.3390/pharmacy14020058

Vancouver

Saramak K, Kaml M, Peball M, Delazer L, Walser G, Hussl A, et al. Lacosamide Safety During Pregnancy and Breastfeeding: A Single-Centre Experience and Comprehensive Narrative Review. Pharmacy. 2026;14(2):58. doi:10.3390/pharmacy14020058

BibTeX
@article{Saramak2026,
  author = {Saramak, Kamila and Kaml, Manuela and Peball, Marina and Delazer, Luisa and Walser, Gerald and Hussl, Anna and Unterberger, Iris and Astner-Rohracher, Alexandra},
  title = {Lacosamide Safety During Pregnancy and Breastfeeding: A Single-Centre Experience and Comprehensive Narrative Review},
  journal = {Pharmacy},
  year = {2026},
  volume = {14},
  number = {2},
  pages = {58},
  doi = {10.3390/pharmacy14020058}
}
Kostenlos starten →